lobbying_activities: 1147027
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1147027 | fa287894-a420-44b6-865a-af8e892638d2 | Q3 | THE PETRIZZO GROUP, INC. | 305932 | FATE THERAPEUTICS, INC. | 2011 | third_quarter | MED | Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine for muscle regeneration by using the fundamental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health. | Defense Advanced Research Projects Agency (DARPA),Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2011-10-12T11:31:28.647000-04:00 |